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Abstract
Background: The release of proteins from tumors can trigger an immune response in cancer patients involving T
lymphocytes and B lymphocytes, which results in the generation of antibodies to tumor-derived proteins. Many
studies aim to use humoral immune responses, namely autoantibody profiles, directly, as clinical biomarkers.
Alternatively, the antibody immune response as an amplification system for tumor associated alterations may be
used to indicate putative protein biomarkers with high sensitivity. Aiming at the latter approach we here have
implemented an autoantibody profiling strategy which particularly focuses on proteins released by tumor cells in
vitro: the so-called secretome.
Methods: For immunoscreening, the extracellular proteome of five colorectal cancer cell lines was resolved on 2D
gels, immobilized on PVDF membranes and used for serological screening with individual sera from 21 colorectal
cancer patients and 24 healthy controls. All of the signals from each blot were assigned to a master map, and
autoantigen candidates were defined based of the pattern of immunoreactivities. The corresponding proteins were
isolated from preparative gels, identified by MALDI-MS and/or by nano-HPLC/ESI-MS/MS and exemplarily confirmed
by duplex Western blotting combining the human serum samples with antibodies directed against the protein(s)
of interest.
Results: From 281 secretome proteins stained with autoantibodies in total we first defined the “background
patterns” of frequently immunoreactive extracellular proteins in healthy and diseased people. An assignment of
these proteins, among them many nominally intracellular proteins, to the subset of exosomal proteins within the
secretomes revealed a large overlap. On this basis we defined and consequently confirmed novel biomarker
candidates such as the extreme C-terminus of the extracellular matrix protein agrin within the set of cancer-
enriched immunorectivities.
Conclusions: Our findings suggest, first, that autoantibody responses may be due, in large part, to cross-
presentation of antigens to the immune system via exosomes, membrane vesicles released by tumor cells and
constituting a significant fraction of the secretome. In addition, this immunosecretomics approach has revealed
novel biomarker candidates, some of them secretome-specific, and thus serves as a promising complementary tool
to the frequently reported immunoproteomic studies for biomarker discovery.
Background
Serological screening methods have been used exten-
sively to identify autoantigens in autoimmune diseases
and in cancer. Various experimental approaches have
been developed that exploit the humoral immune
response in cancer patients to indicate tumor associated
antigens. The experimental methods used and the
results obtained are summarized in a number of recent
excellent reviews [1-6]. For more than two decades,
numerous groups made use of the SEREX (serological
profiling of tumor antigens) technology where recombi-
nant expression libraries are screened with cancer
patient sera. In order to represent more closely the nat-
ural sources of immune responses in cancer patients,
including protein modifications, the proteome of tumors
has, in recent years, been used as the antigen source for
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(serological proteome analysis), AMIDA (autoantibody
mediated identification of antigens) or Proteomex
involves performing 2D-Western blots on tumor lysates
using human cancer sera as the source of antibody. It is
also undertaken with array platforms in order to
increase throughput.
From all of these studies it has become apparent that
autoantibody profiles are highly diversified. This has
recently been illustrated by work from Li et al., who
showed by 2D Western blotting that the serum from
each healthy person comprises an individual pattern of
numerous autoantibodies detecting a highly distinct set
of antigens plus some common frequent targets [7].
Thus, the task of identifying tumor-specific autoantibo-
dies of cancer patients above the background of “consti-
tutive” autoantibody repertoires of unaffected individuals
is most challenging. Apart from their inherent diagnos-
tic value, serum antibodies can be regarded as indicators
of novel tumor biomarker proteins, namely their cog-
nate antigen proteins.
Here, we introduce a novel immunoscreening
approach tentatively termed “immunosecretomics”
which particularly aims at the discovery of biomarker
proteins released by tumor cells (in vitro and) in vivo.
Divergent from and complementary to currently per-
formed proteome based immunoscreening studies we
make use of the extracellular proteome of tumor cells.
The extracellular proteome, tentatively termed the
secretome and defined as the entirety of proteins in
conditioned media (cleared from cellular debris and
apoptotic bodies) is composed of proteins specifically
released through classical secretion and unspecifically
released through cell death. Moreover, prominent con-
stituents of the secretome are delivered through ectodo-
main shedding of transmembrane proteins [8]. Lastly,
membrane vesicles termed exosomes represent an
important component of the extracellular proteome.
Exosomes are derived from an endosomal compartment
and are released via fusion of multivesicular bodies with
the plasma membrane [9-13]. The secretion of exosomes
was first described in immune cells and was later found
to occur in other cell types including tumor cells [14]
and intestinal epithelial cells [15].
For immunoscreening, the extracellular proteome of
colorectal cancer cells was resolved on 2D gels, immobi-
lized on PVDF membranes and used for serological
screening with sera from colorectal cancer patients as
compared to healthy controls. The rationale behind this
approach was twofold: firstly, the release of proteins
from tumors is one of the presumptive mechanisms
initiating an immune response in cancer patients. In
particular, cross-presentation of tumor-derived antigens
to the immune system via engulfment of tumor-derived
exosomes by dendritic cells has been demonstrated [16].
Secondly, the secretome in general is regarded as an
enriched source for biomarker discovery [8,17-23]. The
mechanisms listed above that underlie protein release in
vitro are functional in vivo, as well, and contribute to
the set of proteins most likely reaching the circulation.
In this study, we have performed the immunosecre-
tomics approach described above using individual sera
from 21 colorectal cancer patients and from 24 control
individuals. Autoantibody patterns were assigned to a
secretome master map and two groups of proteins were
further analysed: First, to shed some light on common
features of autoantibody profiles those proteins that
most frequently elicit an immune response in general
were identified by mass spectrometry. As many of these
were nominally intracellular proteins, we experimentally
addressed the hypothesis, that frequently detected anti-
gens were released through exosomes. Subsequently, we
focussed on the candidate tumor associated antigens,
namely those proteins displaying more frequent immune
reactivities in the cancer sera group. These tumor-asso-
ciated autoantigen candidates were assessed by duplex
Western blotting with the combination of an antibody
directed against the protein of interest and serum sam-
ples positive for this candidate autoantigen as a high
stringency criterion for antigen confirmation. Ultimately,
we defined two novel biomarker candidates, namely
Glod4, a poorly characterized glyoxalase-domain con-
taining protein and a C-terminal fragment of agrin, a
prominent large heparansulfate proteoglycan resident in
basement membranes.
Methods
Collection of serum samples from patients with colorectal
cancer and healthy donors
The 45 patients included in our study were recruited
from the German university hospital, Knappschaftskran-
kenhaus Bochum. The personal data of patients were
passed out in an encrypted form by the clinical personal
data management software. All patients and healthy
donors had given written informed consent for use of
the samples in research http://www.ruhr-uni-bochum.
de/ethik/download/Deklaration_Helsinki_2008_engl..pdf,
as approved by the ethics board of the medical faculty of
the university. Patient and healthy donor characteristics
including histopathology data, autoimmune diseases,
allergies and previous malignancies were recorded in an
Access database, a short compilation is given in table 1.
Serum samples were obtained from patients admitted to
surgery for colorectal cancer and prior to other therapy.
The control group was age-matched and in order to
exclude undetected colorectal cancer or adenoma was
recruited from persons who had undergone colonoscopy
with negative results. Venous blood samples were drawn
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BD diagnostics (BD Vacutainer® SST™ Advance 2 ml
tubes), kept at room temperature for 30 minutes, then
centrifuged (10 min at 3000 rpm), separated and frozen
at -80°C in aliquots to prevent freeze thaw cycles.
Cell culture and preparation of the subproteomes
“secretome” and “exosome”
The human colorectal carcinoma cell lines SW948,
SW620, SW480, HT29, CaCo2 were chosen for secre-
tome production. The cell lines SW620 and SW480
were obtained from the American Type Culture Collec-
tion (Rockville, MD, USA), the cell lines HT29, SW948
and CaCo2 were kindly provided by M. Strauss/Berlin.
All cells used to produce conditioned media were
grown in DMEM supplemented with 10% fetal calf
serum, 2 mM glutamine, 100 U/mL penicillin and 100
mg/mL streptomycin until they reached a confluency of
approximately 60-70%. Cells were then washed three
times with DMEM and incubated in serum-free med-
ium supplemented with hydrocortisone at 1 ng/mL and
ITS additives (Sigma, St. Louis, MO, USA) consisting of
5 mg/mL insulin, 5 mg/mL transferrin and 5 ng/mL
sodium selenite for two days. This protocol did not
measurably influence the rate of cell death as deter-
mined by trypane blue exclusion. The conditioned
media of serum-free cell cultures were cooled down on
ice, centrifuged (200 g, 10 min) and passed through 0.2
μm pore filters to remove cellular debris, protected
from proteolytic digestion by adding an inhibitor cock-
tail (7 nM pepstatin, 85 μg/ml PMSF and inhibitor
cocktail complete™ Roche, Mannheim, Germany), and
concentrated by ultrafiltration (Centriplus YM-3, Milli-
pore). The protein concentration of secretomes was
Table 1 Patients and numbers of autoantigens
category UICC stage Localisation of tumor allergy rheumatism diabetes gender f/m age number of autoantigens
CRC I Sigma-Ca f 50 33
II Rectum-Ca m 83 19
II Coecum-Ca m 65 15
II Sigma-Ca m 85 20
4 1/3 71 ± 17 22 ± 8
III Rectum-Ca m 75 28
III Coecum-Ca* f 63 23
III Colon Ca m 81 29
III Rectum-Ca m 76 31
III Colon-Ca* allergy f 58 29
III Colon-Ca* diabetes type II m 78 28
III Rectum-Ca m 70 40
III Rectum-Ca m 45 29
III Colon-Ca m 65 54
9 2/7 68 ± 11 32 ± 9
IV Coecum-Ca f 84 30
IV Rectum-Ca m 68 27
IV Rectum-Ca* m 82 28
IV Sigma-Ca f 48 21
IV Coecum-Ca allergy f 51 23
IV Coecum-Ca allergy f 50 24
IV Coecum-Ca allergy f 83 39
nd Rectum-Ca rheuma m 87 26
8 5/3 69 ± 17 27 ± 6
all CRC 21 8/13 69 ± 14 28 ± 8
CONTROL Colonoscopy result
11 Negative 5/6 55 ± 18 34 ± 13
13 Diverticulosis 7/6 72 ± 7 35 ± 15
4× rheuma 65 ± 16 33 ± 14
CONTROL 24 10× allergy 12/12 20 - 83 7 - 60
4× diabetes 71 ± 6 26 ± 13
Nd not defined; * prior malignant disease
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(BioRad, Hercules, CA, USA).
The enrichment of exosomes was performed as
described by van Niel et al. [24] with modifications. In
brief, secretome samples derived from the five colorectal
carcinoma cell lines used here were subjected to ultrafil-
tration with a cut off at 100 kDa and subsequent ultra-
centrifugation at 120,000 × g for 1 h at 4°C using a
T890 titanium fixed angle rotor (Sorvall, Langenselbold,
Germany). The pellet was resuspended in PBS. Enrich-
ment of exosomes was confirmed by Western blot ana-
lysis of secretome and exosome samples for exosomal
marker proteins such as syntenin, alix, EpCAM, and
Lamp3 [25].
Two-dimensional gel electrophoresis
For 2-D-gel electrophoresis the concentrated proteins
were desalted using Micro Bio-Spin 6 chromatography
columns (Biorad), dried in a Speed Vac and resus-
pended at a final concentration of 10 μg/μli nI E Fs a m -
ple buffer (30 mM Tris-HCl, 2 M thiourea, 7 M urea,
4% CHAPS; pH 8.5). Dithiothreitol (1.08 g/ml, Bio-Rad)
and ampholine 2-4 (GE Healthcare; Freiburg, Germany)
were added to the protein samples to a final concentra-
tion of 75 mM and 2% (v/v), respectively. The protein
samples were separated on 2D-gels in 11 × 14 cm
dimension. Isoelectric focusing of proteins was carried
out by running IEF tube gels (11 cm × 0.9 mm) with
free ampholytes in a self made IEF chamber on a vol-
tage gradient for 15,45 h according to Klose et al. [26].
The tube gels were ejected and equilibrated in 125 mM
Tris buffer (with 40% w/v glycerol, 3% w/v SDS, 65 mM
DTT, pH6,8) for 10 min. The SDS-PAGE (second
dimension) was performed on 15.2% T, 1.2% C polya-
crylamid gels. The IEF tube gels were placed onto gels
11 cm × 14 cm × 0.8 mm and fixed using overlay agar-
ose (Biorad).
2D-Western blotting
Protein samples (180 μg) were separated on 2-D gels (11
× 14 cm) as described above. The secretome proteins
were transferred to a PVDF membrane in a semi-dry
blotting procedure. After blotting the gels were stained
with silver according to Heukeshoven [27] to check for
t h eq u a l i t yo fs a m p l ep r e p a r a tion and electrophoresis;
images were scanned. Only blots with high similarity to
the master gel were further proceeded. The membranes
were blocked for 2 h in blocking buffer (Odyssey block-
ing buffer and PBS, 1:1 with Tween 0.05% v/v) and
incubated with patient sera in a dilution of 1:10 in
blocking buffer for one hour. An anti-human-IgG (Fc)
antibody conjugated with the fluorescent dye IRDye 800
(Rockland) was used as the secondary antibody. Back-
ground “signals” resulting from this secondary antibody
are shown with a Western blot performed with the sec-
ondary antibody, only (additional file 1 figure S1). The
signals were detected using the Odyssey Infrared Ima-
ging System (LI-COR Biosciences) using the same sensi-
tivity for all blots. The threshold for a signal was set to
tenfold above background. Signals were detected with
values varying between 0.2 and 25 (integrated
intensities).
In order to match the immunoreactive spots to the
Master map, each digital Western blot together with the
corresponding silver-stained gel was overlayed to the
Master map using Adobe photoshop software as exem-
plarily shown in additional file 1 figure S2). An antigen
number was assigned to each spot on the master map
detected by antibodies in one or several sera. The auto-
antigen signature of each serum, that is, all of the sig-
nals detected on each individual Western blot, was
translated into the corresponding set of antigen num-
bers and results were recorded in the above mentioned
Access database.
Antigen identification by MALDI-TOF/TOF-MS and
nano-HPLC/ESI-MS/MS
To identify the protein spots of interest 180 μg secre-
tome protein were separated on preparative gels with a
size of 11 cm × 14 cm and 1.5 mm thick applying a
voltage gradient for 14.7 h. Proteins were stained with
an MS compatible silver staining procedure according
to Blum [28]. The spots were manually excised and
processed for mass spectrometry as previously
described [8,17,29]. Tryptic peptides were analysed
with MALDI-TOF/TOF-MS using an ultraflex II™
(Bruker Daltonics, Bremen, Germany) according to the
manufacturer’s instructions. Peptides were spotted
onto an MTP AnchorChip™ 800/384 TF target (Bruker
Daltonics). The target positions were manually coated
with a saturated solution of a-cyano-4-hydroxycin-
n a m i ca c i d( H C C A )m a t r i x .D r i e ds a m p l e sw e r es u b s e -
quently washed with 0.1% TFA to remove sodium and
potassium adducts. The spectra were acquired in the
positive mode with a target voltage of 20 kV and a
pulsed ion extraction of 17.25 kV. The reflector voltage
was set to 21 kV and detector voltage to 1.7 kV. Inter-
nal calibration of peptide mass fingerprint (PMF) spec-
tra was performed using the autolysis products of
trypsin (see additional file 2). PMF spectra were pro-
cessed using the FlexAnalysis™ (v.2.2) software (Bruker
Daltonics). The parameters used for peak-picking were
based on the peak detection algorithm Snap, a signal
to noise threshold of 6, a maximum number of 100
peaks with a quality factor threshold of 50. For subse-
quent protein identification the mass lists were sent to
the ProteinScape™ database (Bruker Daltonics).
Searches were started from ProteinScape™ database,
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COT (v.2.2.0 and v.2.0.04) - search algorithms [30]. A
ProFound score of >1.65 and a Mascot score of >64
was set as threshold for protein identification. The fol-
lowing search parameters were selected: fixed cysteine
modification with propionamide, methionine oxidation
as variable modification, one and two maximal missed
cleavage sites in case of incomplete trypsin hydrolysis,
mass tolerance of 50 and 100 ppm, respectively, a MW
mass range from 5.0 to 250.0 kDa and pI range of 2.0
to 12.0. Searches were run using the human protein
subdatabase of the NCBI (http://www.ncbi.nlm.nih.gov,
June 2003-November 2006). The searches using the
NCBI database were rerun to get actual gi numbers of
the subdatabase (Feb - April 2008).
Peptides from protein spots with a low or no signifi-
cant ProFound Score were automatically selected for
MS/MS using the MALDI-TOF/TOF instrument. The
obtained data were assigned with the SEQUEST™ algo-
rithm [31]. The same search parameters as described
above were used with the following exception: the pep-
tide mass tolerance was set at 0.5 Da for monoisotopic
masses and at 0.3 Da for fragment masses. A SEQUEST
s c o r eo f>1 . 5f o ras i n g l ep e p t i d ew a ss e ta st h r e s h o l d
for protein identification. All searches were repeated
using the same parameters except that the taxonomy
was extended to mammalia, in order to identify putative
contaminating bovine proteins originating from fetal calf
serum in the culture media. All identified protein spots
were depicted in the additional file 2. The mass lists and
spectra of identified antigens described in table 2 and 3
were shown in additional file 3.
Antigens not identified by MALDI-MS(/MS) or not
confirmed by duplex Western blots with specific antibo-
dies were reanalyzed by nano-HPLC/ESI-MS/MS on a
high capacity ion trap instrument (HCT plus, Bruker
Daltonics). To this end, tryptic peptides were generated
and extracted twice from the gel with 50% ACN/2.5%
formic acid [50:50 (v/v)]. Online reversed-phase capil-
lary HPLC separations were performed on a Dionex LC
Packings HPLC system (Dionex LC Packings, Idstein,
Germany) as described by Schäfer et al. [32]. The mass
spectrometer was operated in the sensitive mode with
the following parameters: capillary voltage 1400 V; end
plate offset, 500 V; dry gas, 10.0 l/min; dry temperature,
160°C; aimed ion charge control 150000; maximal fill-
time 500 ms. The nano-ESI source (Bruker Daltonics,
Germany) was equipped with distal coated SilicaTips
(FS360-20-10-D; New Objective). MS spectra were the
sum of seven individual scans ranging from m/z 300 to
m/z 1400 with a scanning speed of 8,100 (m/z)/s. Data-
dependent software (HCT plus, Esquire Controle, Bru-
ker Daltonics, Germany) was employed to select the
two most intense, multiple-charged peptide ions
detected within the MS spectra to subsequently conduct
MS/MS fragmentation analysis. Low energy collision-
induced dissociation (CID) was performed on isolated
peptide ions by applying a fragmentation amplitude of
0.6 V. Generally, MS/MS spectra were the sum of four
scans ranging from m/z 100 to m/z 2200 at a scan
rate of 26,000 (m/z)/s. Exclusion limits were automati-
cally placed on previously selected mass-to-charge
ratios for 1.2 min. The ion trap instrument was exter-
nally calibrated with commercially available standard
compounds.
Peaklists of MS/MS spectra were generated using the
software Data-Analysis 3.3 with default parameters. For
peptide and protein identification, peaklists were corre-
lated with the human International Protein Index
(Human IPI V3.54) http://www.ebi.ac.uk database con-
taining 75426 protein entries using MASCOT (release
version 2.2.0) [33]. All searches were performed with
tryptic specificity allowing one missed cleavage. Oxida-
tion of methionine was considered as variable modifica-
tion. Mass spectra were searched with a mass tolerance
of 1.2 Da for precursor ions and 0.4 Da for fragment
ions and MS/MS spectra were accepted with a mini-
mum MASCOT score of 20. Proteins were assembled
on the basis of at least two peptides and a false discov-
ery rate (FDR) of 0% using the ProteinExtractor Tool
(version 1.0) in ProteinScape (version 1.3, Bruker Dal-
tonics). The FDR was calculated as described [34] and is
the quotient of the number of all proteins identified in a
shuffled database and the sum of all protein identifica-
tions in both the human IPI database and its shuffled
version. Details of the antigens (data and spectra) identi-
fied by nano-HPLC/ESI-MS/MS were depicted in addi-
tional file 4.
Confirmation of autoantigen identification by duplex
Western blotting
Western blotting with individual human serum samples
was performed as described above using a secondary
antibody conjugated with the fluorescent dye IRDye 800.
Subsequently, the blot was reprobed with one of the
specific antibodies recognizing syntenin (Synaptic Sys-
tems 133002, 1:1000), PGAM1 (Abcam, ab 2220,
1:1000), Aldolase C (D14; Santa Cruz sc-12066; 1:1000),
Vip36 (V-20; Santa Cruz, sc-32441; 1:1000) or Agrin (K-
17; Santa Cruz, sc-6166; 1:250), respectively. These pri-
mary antibodies were detected with species-specific sec-
ondary antibodies (goat, rabbit or mouse) each
conjugated with the fluorescent dye Alexa Fluor 680
(Rockland). Signals derived from the human serum and
from the specific antibodies were scanned at the appro-
priate wavelengths with the Odyssey Infrared Imaging
System (LI-COR Biosciences) and can be depicted sepa-
rately or combined.
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The significance of differential immunreactivities of
patient versus control sera with a particular antigen was
tested with Fisher’s exact test with a p-value of 0.05.
T h ed a t aa n a l y s e sw e r ep e r f o r m e du s i n gG r a p h P a d
Prism version 4.00 for Windows (GraphPad Software,
San Diego California USA, http://www.graphpad.com).
Results and discussion
Autoantibody profiling on 2D Western blots of secretome
proteins with sera from colorectal cancer patients as
compared to healthy controls
For autoantibody profiling serum samples were obtained
from 21 patients, diagnosed with colorectal cancer and
prior to therapy. As a reference to the identification of
disease-specific autoantibodies, we used serum samples
from 24 age-matched control individuals, all of whom
were negative for any other known malignancy and pre-
cancerosis. Patient and control individual characteristics
are listed in Table 1.
To establish autoantibody profiling for colorectal can-
cer we initially performed 1D Western blotting using
cell lysates and secretomes in parallel. Whereas the pat-
terns obtained with the secretome as the antigen source
appeared less complex as compared to the pattern on
cell lysates we also observed secretome-specific reactiv-
ities (data not shown). We have reported previously,
that the “secretome” here defined as the entirety of pro-
teins released into the conditioned media represents a
distinct subproteome displaying some overlap with the
corresponding cell lysate but also harbouring numerous
secretome-specific proteins (additional file 1 figure S3).
Moreover, we observed that the secretomes derived
from individual cell lines significantly differed from each
other (data not shown). In order to obtain a representa-
tive colorectal cancer secretome, we decided to use five
human colorectal cancer cell lines for secretome pro-
duction and to pool the secretomes in equal amounts. A
comparison of the antigen pattern derived from test sera
on this pooled secretome sample resolved on a two-
dimensional gel as compared to tumor cell lysates con-
firms that our approach is complementary to the “stan-
dard” immunoscreening methods in current use (data
not shown). The secretomes were subsequently used for
autoantibody profiling by 2D Western blotting with
patient and control sera.
The experimental work-flow is depicted in Figure 1.
In brief, a secretome master map was prepared by sil-
ver staining of the secretome pool resolved on a 2D
gel (Figure 2a). All 21 patient and 24 control sera were
investigated individually by 2D Western blotting for
the presence of antibodies to secretome proteins. All
of the signals from every blot were assigned to the
master map and autoantigen candidates were isolated
from preparative gels. Protein identification was per-
formed by MALDI-MS and by nano-HPLC/ESI-MS/
MS. Selected candidates were confirmed by Western
blotting with specific antibodies.
The nature and condition of the antigen source used
for immunoscreening as well as details of the experi-
mental protocol strongly influence the results of a parti-
cular study. This study significantly varies from
previously published approaches in several aspects:
Firstly, we have used the Odyssey system for signal
detection. Primary antibody reactivities (in the case of
this study: serum autoantibodies) are detected by a sec-
ondary antibody directly coupled with a fluorescent dye
and signals are obtained with a near-infrared light scan-
ner. In contrast to the currently used chemolumines-
cence based systems this detection method is
independent of enzymatic signal amplification and
allows for semiquantitative assessment of signals. More
importantly, signals can be detected whose intensities
vary for three to four orders of magnitude. We believe
this to be an invaluable advantage, in particular when
complex patterns of autoantibody reactivities are deter-
mined on 2D Western blots. Secondly, the Odyssey sys-
tem allows for signal detection in two channels and
enables duplex Western blotting. Thus, confirmation of
autoantigen candidates via Western blotting with a spe-
cific antibody can be performed with unprecedented
exactness, as human serum reactivities and signals
derived from the specific antibody can be detected on
the same blot. Lastly, where unequivocal protein identi-
fication via MALDI-MS was not feasible or where candi-
dates were disproven we here performed additional
nano-HPLC/ESI-MS/MS analyses of proteins cut from
2D gels as apparent single protein spots. Results pre-
sented below illustrate that this approach in combina-
tion with duplex Western blot confirmation can prevent
misinterpretation of results.
Western blotting with individual sera showed that
each serum - whether patient or control - gave rise to
an individual complex autoantibody profile on the col-
orectal cancer secretome (see Figure 2b for examples).
All proteins that stained with autoantibodies - 281 in
total - were assigned to a master map of the colorectal
carcinoma cell secretome and the detection frequency
of each antigen with patient versus control sera was
plotted. The number of antigens detected by each
serum sample is shown in additional file 1 figure S4
for the control and the CRC group, respectively and
provided in table 1 for the individual CRC sera. The
majority of the sera displayed between 20 and 40 sig-
nals. We cannot confirm previous reports by some
researchers that cancer patients possess more or stron-
ger autoantibody reactivities as compared to controls.
Rather, five of the six serum samples which show more
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additional file 1 figure S4). In addition, we did not
detect any dependency of antigen numbers on age or
gender of the serum donors. Moreover, diseases asso-
ciated with autoimmune processes like rheumatism
and diabetes as well as allergies which were repre-
sented in the cancer and control groups in a few cases
did not detectably impinge on the frequency of autoan-
tigen detection.
Each antibody reaction derived from each serum was
assigned to a protein spot on the master gel (see meth-
ods section for details and additional file 1 figure S2 for
illustration). Together, the patient sera detected 179 dif-
ferent protein spots, the control sera 240; bringing the
total number of protein spots/autoantigens detected in
this study to 281 (all reactivities for each serum sample
are individually shown in additional file 5). Of these 281
autoantigens, about 30% were detected only once by one
individual serum, each, and more than 50% of antigens
were detected by 2-10 sera; 10% of antigens were
detected by 10-20 of the 45 serum samples and 16% of
proteins were detected by the corresponding autoantibo-
dies in more than 20 sera. These results are consistent
with a study by Li et al. who analysed autoantibody pro-
files of healthy Chinese people and reported that a very
broad spectrum of self components could be recognized
by the immune system [7]. When we plotted autoanti-
body frequencies separately for the cancer and control
group, we observed a higher diversity of autoantibodies
in the group of control sera (Figure 3).
A large fraction of autoantigens displaying frequent
immunoreactivity are exosomal proteins
We were most interested in two aspects of this autoanti-
body profile: firstly, which proteins most frequently elicit
an autoantibody response in general and secondly,
which antigens most frequently elicit autoantibodies in
the disease group? Correspondingly, we aimed to iden-
tify, firstly, those antigens detected by more than 20 sera
in total and secondly, those antigens, which are more
frequently detected by patient sera. The corresponding
protein spots were assigned to preparative gels, the
spots were isolated and tryptic peptides analysed by
MALDI mass spectrometry and database searches.
Antigens detected by more than 20 sera are listed in
table 2; another 45 antigens identified by mass spectro-
metry are listed in additional file 2. Three proteins,
namely transferrin, triosephosphate isomerase and eno-
lase are detected by virtually each serum sample. The
detection of transferrin by autoantibodies in every
serum sample may be due to the experimental design:
large amounts of transferrin (roughly one fourth of the
total protein, added as a culture medium supplement)
are present in the secretomes and are presented to the
patient samples. Triosephosphate isomerase and enolase
were also detected by 45/45 and 44/45 serum samples.
Figure 1 The immunosecretomics workflow. Secretomes are prepared from five human colorectal carcinoma cell lines. A 2-dimensional
secretome master map is established. Corresponding 2-dimensional Western blots are prepared using individual sera from CRC patients and
healthy controls to indicate autoantigens. Signals derived from autoantibodies in the sera are matched to the master map, corresponding
proteins are excised from preparative gels and identified by mass spectrometry and database searches. Ultimately, the autoantigen candidates
are confirmed by duplex Western blotting with human sera and with specific antibodies directed against the protein of interest.
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Page 9 of 19Figure 2 The secretome master map and exemplary 2-D Western blots. Secretome proteins are separated by 2-D PAGE and stained with
silver to serve as a master map (a). Numbers indicate the spots detected by one or several sera on corresponding 2-D Western blots. Figure 2b
provides examples of 2-dimensional Western blots with individual sera from CRC patients and healthy controls.
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the frequently detected proteins are intracellular pro-
teins. Their preponderance among proteins detected by
autoantibody profiling on cellular secretomes appears
surprising at first glance.
Likewise, the large overlap of proteins identified in
this immunosecretomics approach as compared to other
studies using cell lysates as an antigen source came as a
surprise. For example, Li et al.w h op r o f i l e d3 6s e r u m
samples from healthy Chinese individuals for autoanti-
bodies also detected enolase, phosphoglycerate mutase
and triosephosphate isomerase among the most fre-
quently immunoreactive proteins in lysates of a glioma
cell line [7]. Thus, we sought for an explanation for
these findings.
Analysing the composition of secretomes in more
detail we found previously that a significant fraction of
secretome proteins is contributed through the release of
exosomes. We wished to experimentally analyse if the
autoantigens as defined here may be of exosomal origin.
To that end, we isolated the exosomal fraction of the
secretome pool and performed 2D gel electrophoresis.
Through an overlay of the secretome master map and
the exosomal protein pattern, immunoreactive proteins
were assigned to the exosome fraction (Figure 4). About
one third of all antigens defined by our approach over-
lapped with spots in this exosomal preparation. More
than 60% of these antigens belong to the frequently
reactive antigen group including enolase, phosphoglyce-
rate mutase and triosephosphate isomerase (compare
Table 2). In addition, whereas aldolase, cyclophilin A
and cofilin could not unequivocally be assigned to the
exosomal protein fraction by this image analysis, we and
others have also previously detected these three proteins
in catalogues of exosomal proteins [35]. These results
confirm our assumption, that the abundance of nomin-
ally intracellular proteins within the antigenic secretome
proteins is due to exosomes. Moreover, these findings
may underline the involvement of exosomes in the regu-
lation of immune responses - either induction of toler-
ance or immune defense [36-38]. Another protein in the
list of the most frequently detected antigens is the
Figure 3 Diversity of autoantibody signatures. The numbers of antigens reactive with 1, 2, 3 and more sera are plotted individually for the
control and the CRC group, indicating a higher diversity of autoantibodies in the group of healthy controls.
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Page 11 of 19secreted protein cystatin SN; it is detected by 35 of the
45 sera. Cystatin SN belongs to a family of cystein pro-
teinase inhibitors and is characterized as a salivary cysta-
tin. Autoantibodies detecting cystatins, to our
knowledge, have not yet been reported. Interestingly,
whereas the normal intestinal epithelium does not
express cystatin SN, its expression has been found in
colorectal adenomas in an RNA-based profiling study
[39]. The frequency of autoantibodies against cystatin
SN, however, does not significantly differ between the
patient and control groups.
Of interest, some of the most frequently reactive pro-
teins listed in table 2 have previously been detected as
tumor-associated antigens (compare additonal file 6 for
a compilation of published antigen frequencies). For
example, 47% of sera from HCC patients reacted with
STIP1 [40] and 50% of sera from esophageal cancer
patients detected peroxiredoxin [41], whereas the fre-
quencies with control sera were reported with 10% and
less in these studies but displayed 71% in our study.
Likewhise, DeMonte et al. found 36% positivity for aldo-
lase A with sera from colorectal cancer patients and
15% with control sera whereas 76 and 75% of CRC and
control sera were positive in our study [42]. Due to the
variability in experimental approaches and materials
used it is not feasible to directly compare results from
different SERPA-based studies. We believe, however,
that the use of the secretome as a complementary
Figure 4 Comparison of secretomes and exosomes. An enriched exosome preparation was separated by 2-D PAGE and stained with silver.
This exosome “master map” depicted in red was overlayed onto the secretome master map, here shown in blue using Adope Photoshop
software. Frequently detected autoantigens are strongly represented in the exosome fraction (compare tables 2 and 3).
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its capacity to determine widely varying levels of signal
intensities have a strong impact on the results.
Identification of cancer-enriched autoantigens
On this basis we next sought to identify cancer-specific
or cancer enriched autoantigens in the colorectal cancer
secretome. In total, we defined protein spots which were
detected with at least three more cancer than control
sera or detected exclusively with at least two cancer
sera. The corresponding proteins were isolated from
preparative gels and proteins were subject to MALDI-
TOF/TOF-MS. In some cases two proteins were identi-
fied from one spot; proteins from two spots - 62a and
74a - were both identified as LMAN2. Again, with the
exception of spots 62a and 74a and spot 23 (identified
as agrin), these proteins showing cancer-enriched immu-
noreactivity could be assigned to the exosomal fraction
of the secretome. LMAN2 is an intracellular lectin. It is
a type I membrane protein localized to vesicles that
cycle between the endoplasmic reticulum (ER) and the
Golgi apparatus and is involved in glycoprotein sorting
and trafficking [43,44]. The theoretical and the experi-
mental masses for LMAN2 are consistent, indicating
that LMAN2 is present in the secretome as an intact,
full-length protein.
Agrin, the protein identified in spot 23, is a secreted
extracellular matrix protein. It is a heparan sulfate pro-
teoglycan of more than 200 kDa in size and is a major
component of basement membranes [45-47]. Here, a
protein with an apparent molecular mass of about 20
kDa was identified as agrin by MALDI-MS. We
hypothesized that this protein spot was due to proteoly-
tic processing of full-length agrin. We assigned all seven
peptides identified in repeated attempts of protein iden-
tification for this spot to full-length agrin and found
that all of them mapped to the extreme C-terminus of
approximately 200 amino acids. The theoretical pI of
this fragment (5.5) is consistent with the experimental
pI of 5.2. It is known that agrin is expressed by alterna-
tively spliced mRNAs giving rise to protein products
with slightly different sizes. Moreover, agrin can be cut
by MMP3, which leads to the release of the C-terminal
half of the protein [48]; other not yet exactly defined
fragments have been reported [49]. Neither full-length
agrin nor any fragments thereof have previously been
identified as autoantigens before.
Confirmation of cancer-enriched autoantigens via
duplex Western blot analyses
The more our insight into the composition of cellular
secretomes is increasing the more we learn about the
complexity of this subproteome. Here we used medium-
sized 2D gels for autoantibody profiling, the resolution
of which is limited. Data compiled in tables 2 and 3
illustrate that more than one protein may reside in each
protein spot isolated from preparative gels as expected.
Thus, it is imperative to perform further studies for con-
firmation of autoantigen identification. To this aim we
have used duplex Western blotting where specific anti-
bodies to our autoantigen candidates were available.
Spot 31 was identified as PGAM1 and displayed reac-
tivity with 14/21 CRC sera but with 8/24 control sera,
only. The adjacent spot 30 was also identified as
P G A M 1a n di st h em o r ef r e q u e n ta n t i g e nb u tt h e1 8
sera from CRC patients and controls display no differ-
ence in reactivity (13/21 and 13/24). The specific anti-
body detected spot 31 in seven 2D-duplex Western
blots performed with seven individual sera, positive for
s p o t3 1a n ds p o t3 0( F i g u r e5 a ) .T h i sr e s u l tw o u l d
usually be rated as an unequivocal confirmation of
PGAM1 as a cancer enriched autoantigen. However, the
s p e c i f i cP G A Ma n t i b o d yi na d d i t i o nt os p o t3 1a l s o
detects the adjacent spot 30. This finding may suggest
that the reactivity of patient sera directed against
PGAM1 is isoform-specific. On the other hand it cannot
be excluded, that an additional protein, unrelated to
PGAM1 and not yet identified may reside in spot 31 to
give rise to the differential immunoreactivities of CRC
versus control sera. Support for this alternative hypoth-
esis comes from the observation, that the exosomal pro-
tein fraction displays a larger protein spot at position 31
as compared to 30 whereas the secretome, by contrast,
shows a larger spot at position 30 (compare figure 4).
Ongoing experiments aim to clarify this complex issue.
Spot 41, identified as syntenin, was another candidate
differentially reactive with cancer versus control sera (8/
21 versus 5/24 respectively), although this difference did
not reach significance when a Fisher exact test was per-
formed (table 3). Spot 41 confirmed to represent the
main signal detected by a syntenin-specific antibody. All
control and CRC sera positive for spot 41 were individu-
ally retested in duplex Western blots with the syntenin-
specific antibody. All signals with the exception of one
CRC serum were confirmed to coincide with the main
syntenin spot as detected by the specific antibody (Fig-
ure 5b). In conclusion, there is no doubt that syntenin is
the protein reactive with cancer and control sera in spot
41. The difference in frequency of immunoreactivity
with cancer versus control sera, however, is moderate,
only.
The next candidate protein on our list of cancer
enriched autoantigens is the extreme C-terminal frag-
ment of agrin (Spot 23). A purified goat polyclonal anti-
body directed against a C-terminal agrin peptide
localised to this region is commercially available. Using
this serum on duplex Western blots with three indivi-
dual human sera unequivocally confirmed the identity of
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Page 13 of 19Figure 5 Three examples of confirmation of antigen identification: PGAM1, syntenin and agrin by duplex Western blotting.S p o t s
number 30 and 31 were both identified as PGAM1 by mass spectrometry. 2-D Western blots were performed with seven individual human sera
and detected with a secondary antibody conjugated with the fluorescent dye IRDye 800 as described before. The blots were then reprobed with
a PGAM1-specific antiserum that was detected with a secondary antibody coupled with Alexa Fluor 680, confirming the identity of spots 30 and
31 as PGAM1 in every case. Three examples for the confirmation of PGAM1 as the antigen number 31 are shown (a). Spot number 41 was
reactive with 8/21 CRC and with 5/24 control sera. All positive sera were used in duplex Western blots with a syntenin-specific antiserum,
confirming the correct assignment of immunoreactions for all but one (CRC) serum. Representative examples are depicted (b). Spot number 23
displaying an experimental mass of 23 kDa was identified as agrin, a large glycoprotein (>200 kDa) of the extracellular matrix. Duplex Western
blotting with an antiserum directed against the C-terminal fragment confirms the identity of spot 23 as an agrin fragment presumably generated
by proteolytic processing (c).
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Page 14 of 19the agrin fragment in spot 23 (Figure 5c). In addition, a
second protein spot additionally detected by the specific
agrin serum at a slightly more acidic pI was also
depicted by two of the three human sera.
Spot 69b, exclusively detected with three CRC sera,
was identified as aldolase C. This spot resides in a gel
region with numerous spots in close proximity to each
other. The aldolase C specific antibody stained a protein
spot at the same molecular weight, but with a slightly
different pI (Figure 6a). Further attempts for correct
identification of spot 69b by mass spectrometry have
been undertaken and have provided the same result:
aldolase C. This finding suggests that the antigen resid-
ing in spot 69b may be another isoform of aldolase C,
which is not detected by the commercial antibody.
Two spots, spots 62a and 74a, reactive with 9 versus 2
and 6 versus 0 (CRC versus control respectively) sera
were identified as LMAN2 (lectin, mannose-binding 2),
synonymous with VIP36. A VIP36 specific antibody had
a staining pattern characteristic of a glycoprotein: a
chain of four protein tracks extended in the second
dimension was stained (Figure 6b). Both spots identified
as VIP36 reside within these protein tracks confirming
the exact assignment of the serum derived signals to the
master secretome and to the preparative gel. However,
the serum derived signals are clear-cut spots rather than
tracks of proteins. One might speculate, that serum anti-
bodies may detect unglycosylated LMAN2 proteins,
only. However, upon duplex Western blotting it became
apparent that spot 62a is also slightly shifted towards
the left margin of the respective protein track (Figure
6b). In conclusion, although the assignment of both
spots was highly reliable, we do not believe that the
serum derived signals correspond to the LMAN2
protein.
As both spots displayed significant differences in
reactivities with patient versus control sera, we further
attempted to conclusively identify the autoantigen(s)
corresponding to spots 62a and 74a. To that end,
increased amounts of secretome proteins were resolved
on another preparative gel and stained with Krypton
(detectable at near-infrared wavelengths). The protein
tracks characteristic for Vip36 were used for orienta-
tion, spots 62a and 74a were excised again and subject
to nano-HPLC/ESI-MS/MS (see additional file 4). In
both spots, LMAN2/VIP36 was again identified as
expected (4 and 8 peptides, respectively). Moreover,
several peptides corresponding to keratins were
detected in these spots. In Spot 62a, ten peptides were
identified corresponding to a protein called Glod4.
This spot was detected by 9/21 patient sera, and by 2/
24 control sera. Glod4 is a glyoxalase-domain contain-
ing protein also known as HC71, CGI-150 or C17orf25
and belongs to the glyoxalase I family [50]. Glod4 does
Figure 6 Two examples of disproving antigens: aldolase C as
the antigen in spot number 69b (a) and LMAN2 as the antigen
in spots number 62a and 74a (b). A protein assigned to the
immunoreactive spot 69b was excised from a preparative gel and
identified as aldolase C. Duplex Western blotting with a human
serum and an antibody directed against aldolase C does not show
overlapping signals (a). The immunoreactive protein spots 62a and
74a were excised from a preparative gel and both identified as
LMAN2 (VIP36). A VIP36-specific antibody showed a complex
staining pattern consisting of a chain of four protein tracks
extended in the second dimension. The spots 62a and 74a reside
within or very close to one of these tracks. The staining patterns of
the human sera and the VIP36-specific antibody, however, do not
correspond to each other (b).
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assign it to the exosomal fraction, either. However, evi-
dence for its extracellular occurrence has been pro-
v i d e db yas t u d yo fM o l i n ae ta l .[ 5 1 ] ,a n db yC h e ne t
al. [52] who performed proteomic analyses of human
hemodialysis fluid and of pancreatic juice, respectively,
in order to identify biomarker candidates. Moreover,
Glod4 is also included in the reference list provided by
Li et al. which comprises > 50 proteins identified as
autoantigens in healthy Chinese individuals [7].
Expression patterns of Glod4, molecular functions and
its role in carcinogenesis have not yet been addressed.
In spot 74a, 3 peptides were identified corresponding
to Rad23b, a nucleotide excision repair protein. This
scaffold protein has a central function in DNA repair
and proteasomal degradation [53]. Genetic variations of
nuclear excision repair proteins including Rad23b have
been reported to confer an increased risk for bladder
cancer [54] and are involved in the resistance of cancer
cells to chemotherapeutic drugs [55]. The applicability
of antigen Rad23b as a cancer biomarker will be
assessed in future investigations.
Conclusions
Immunoscreening approaches aimed at the identification
of tumor-associated autoantigens have been published in
large numbers. Yet, the molecular mechanisms that con-
tribute to the profile of autoantibodies in an individual
are poorly understood. Hitherto, a major conclusion
from immunoscreening in healthy and diseased patients
is that the immune response is a peculiarity of each
individual and is highly diversified. Cancer-specific auto-
antibodies directed against each specific protein, on the
other hand, are depicted at low frequencies, with few
exceptions. Consequently, the use of autoantibodies as a
diagnostic tool will need multiplexing, to reach sufficient
sensitivity and specificity.
Immunoscreening may be a valuable tool for the identi-
fication of novel protein biomarkers (the corresponding
autoantigens), in particular for serum-based biomarkers.
Tumors are thought to release many proteins into the
blood. Diagnosing cancer through serum-based analyses is
therefore an attractive concept. The direct identification of
cancer-specific proteins in blood samples, however, is a
very compelling task, due to the complexity and to the
large dynamic range of the plasma proteome. We have
previously suggested the use of the extracellular proteome
of cultured tumor cells as an enriched source for blood-
based biomarkers. Here, we employ this specific subpro-
teome for immunoscreening, using the humoral immune
response of patients as an amplification system to indicate
promising biomarker candidates.
Whereas this work to the best of our knowledge is the
first to use the extracellular proteome as an antigen
source for immunoscreening we find a large overlap
between proteins identified in this study with those
reported in previous work on tumor (cell) lysates by
others (see additional file 6 for details). The appearance
of nominally intracellular proteins in the extracellular
proteome appears surprising at first glance. We could,
however, show that most of the nominally intracellular
autoantigens can be released from tumor cells as exoso-
mal components. Exosomes are microvesicles derived
from late endosomal compartments and implicated in
many forms of intercellular communication [11,12,56].
As shown by Wolfers et al. tumor-derived exosomes
can be engulfed by dendritic cells and initiate cross-pre-
sentation of tumor-specific antigens [16]. Exosomes con-
stitute a significant part of the cellular secretome; so,
high efficiency detection of exosomal proteins by serum
antibodies is consistent with current knowledge. This
finding also contributes to our understanding of the
molecular mechanisms editing the autoantibody profile
of an individual.
The immunosecretomics approach has led to the iden-
tification of known and novel biomarker candidates.
Ubiquitously expressed proteins like PGAM1 and synte-
nin may not represent promising markers: the release of
such proteins by many cell types in the body including
hematopoetic cells would presumably confound sensitive
detection of a tumor-specific release. This argument
may also hold for Glo1 and Glod4. Interestingly, how-
ever, the overexpression of Glo1 in human colon tumors
has previously been reported [57]. Although the fre-
quency of autoantigens directed against Glo1 was low
(two CRC sera, 9.5%), only, an analysis of its differential
release from tumor versus normal cells presumably via
exosomes should be addressed. Along the same lines
Glod4 may deserve further attention as a biomarker
candidate. Expression patterns of Glod4, molecular
functions and its role in carcinogenesis have not yet
been addressed.
A promising novel biomarker candidate identified in
this study is the extreme C-terminal fragment of agrin.
Agrin is a large multidomain heparan sulfate proteogly-
can localized to basement membranes and expressed in
several tissues [45-47]. Well described functions of agrin
are the formation of neuromuscular junctions and acet-
ylcholine receptor clustering in the central nervous sys-
tem. Little is known yet about agrin’sr o l ei n
carcinogenesis. Interestingly, upregulation of agrin in
primary liver cancers has recently been described [58].
Of note, whereas strong expression of agrin was
observed in basement membranes of well and moder-
ately differentiated cholangiocarcinomas, agrin staining
was fragmented, decreased or even absent in poorly dif-
ferentiated carcinomas, presumably reflecting the disin-
tegration of the basement membrane upon local
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teolytic processing of agrin is involved in such progres-
sion-associated disappearance of agrin from basement
membranes. Conversely, agrin processing products like
the C-terminal fragment identified in this study as a
tumor-associated antigen may be released into the circu-
l a t i o n .T h i sh y p o t h e s i sa sw e l la st h es u i t a b i l i t yo ft h e
C-terminal agrin fragment as a biomarker will be
assessed in ongoing studies.
Additional file 1: Details of experimental procedures and results.
Figure S1. Background signals due to secondary antibody. 2D Western
blot of secretome proteins was performed using the secondary antibody
directly. Figure S2. Alignment of individual Western blot signals to the
proteins on the Master map. The figure exemplarily illustrates the
alignment of Western blot signals to the master gel by overlaying the
digital pictures of the master gel (depicted in blue), the silver stain of an
individual gel after blotting (in green) and the corresponding Western
blot signals (in red). The patterns can be manually aligned by moving
the pictures towards each other in the overlay to correct for regional
differences in the gel runs. Figure S3 Comparison of patterns from
tumor cell lysates versus secretome. A secretome sample (green) and a
lysate sample (red) of a colorectal cancer cell line were resolved in the
same 2D-PAGE using the DIGE technology (for details see protocols of
GE healthcare and reference 8. Proteins which appeared in both samples
are shown in yellow, whereas protein spots in red or green are unique
to the respective sample. Figure S4 Total number of immune reactions
per serum in the cancer and the control group. The number of antigens
identified with each individual serum sample is depicted.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
70-S1.PDF]
Additional file 2: Antigens identified by MALDI. Table of calibrants
and table of all identified antigens by MALDI including antigens given in
table 2 and 3.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
70-S2.XLS]
Additional file 3: Details of identification by MALDI. PMF spectra and
mass lists of antigens given in Table 2 and 3.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
70-S3.XLS]
Additional file 4: Antigens identified by nano-HPLC/ESI-MS/MS.
Summary of data analysis and table of identified antigens.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
70-S4.PDF]
Additional file 5: Compilation of individual autoantibody profiles.
Numbers of immune reactions for all individual sera.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
70-S5.XLS]
Additional file 6: Autoantigens reported in the literature. Examples
of autoantigens and their frequencies reported in the literature.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
70-S6.PDF]
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AG: antigen; CRC: colorectal carcinoma; Ca: carcinoma; 2D: two dimensional;
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matrix-assisted laser-desorption ionisation; PMF: protein mass finger print;
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